Current Perspectives and Progress in Preoperative Portal Vein Embolization with Stem Cell Augmentation (PVESA)

Area of Science:

• Hepatology and Regenerative Medicine
• Surgical Oncology
• Stem Cell Therapy

Background:

• Conventional portal vein embolization (PVE) for future liver remnant (FLR) growth has limitations in patients with liver dysfunction.
• PVESA is an emerging technique combining PVE with stem cell therapy to improve FLR regeneration.
• Stem cells can enhance liver growth via paracrine signaling or differentiation into hepatocytes.

Purpose of the Study:

• To evaluate the efficacy and safety of PVESA for enhancing FLR growth in liver cancer patients.
• To explore the potential of various stem cell types in augmenting liver regeneration post-PVE.
• To identify areas for optimization and future research in PVESA.

Main Methods:

• Review of preclinical and clinical studies on PVESA.
• Analysis of stem cell types used, including mesenchymal stem cells (MSCs) and hematopoietic stem cells.
• Assessment of safety and efficacy data regarding FLR size and function.

Main Results:

• PVESA has demonstrated general safety and enhancement of liver growth following PVE.
• Clinical studies show benefits from CD133+ bone marrow-derived MSCs and hematopoietic stem cells.
• Preclinical models utilized MSCs, unrestricted somatic stem cells, and small hepatocyte-like progenitor cells.

Conclusions:

• PVESA shows promise for improving FLR growth and function in liver surgery candidates.
• Optimization of stem cell selection, collection, and application is critical for maximizing PVESA benefits.
• Further research, including mechanistic studies and larger clinical trials, is warranted to fully establish PVESA's potential.